This invention involved hybrid nanoparticles using PEG-MAL-modified 2D black phosphorus for targeted photothermal immune composite therapy of HER2-positive breast cancer with higher drug loading and photothermal conversion rates. This evidence concerns the gene ERBB2 and breast carcinoma.